TOKYO—Fujifilm Holdings Corp. said Wednesday it will seek regulatory approval as early as October for the use of its antivirus drug Avigan to treat patients infected with the coronavirus, as clinical tests have shown efficacy in easing symptoms.
According to analysis of data on 156 patients without severe symptoms, Fujifilm found those administered with Avigan show improvement after 11.9 days, shorter than the 14.7 days for those in a placebo group.
Read more.
You may also like these stories:
Japan to Ease COVID-19 Entry Ban to Allow Long-Term Stays
India’s Taj Mahal Reopens to Visitors After More Than Six Months
Legendary Sherpa, 1st to Conquer Everest 10 Times, Dies at 72
Your Thoughts …
